Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Short Interest Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the recipient of a significant growth in short interest in June. As of June 15th, there was short interest totaling 193,285 shares, a growth of 513.6% from the May 31st total of 31,498 shares. Based on an average daily volume of 12,405,724 shares, the days-to-cover ratio is presently 0.0 days. Currently, 4.6% of the company’s stock are sold short.

Cyclacel Pharmaceuticals Price Performance

Shares of BGMS stock traded down $0.00 on Friday, hitting $0.60. The company’s stock had a trading volume of 38,690 shares, compared to its average volume of 7,035,767. Cyclacel Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $19.87. The firm’s fifty day moving average price is $0.95 and its 200-day moving average price is $1.10. The stock has a market capitalization of $3.32 million, a price-to-earnings ratio of -0.13 and a beta of -0.40.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last posted its earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.